Esther Rajavelu Sells 20,689 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) CFO Esther Rajavelu sold 20,689 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total transaction of $16,137.42. Following the completion of the transaction, the chief financial officer now directly owns 724,720 shares of the company’s stock, valued at $565,281.60. This represents a 2.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Spero Therapeutics Stock Performance

SPRO opened at $0.82 on Friday. Spero Therapeutics, Inc. has a one year low of $0.74 and a one year high of $1.89. The company has a market cap of $44.62 million, a P/E ratio of 11.69 and a beta of 0.61. The business’s 50-day simple moving average is $0.99 and its 200-day simple moving average is $1.19.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. TD Cowen reiterated a “hold” rating on shares of Spero Therapeutics in a report on Monday, November 18th. Evercore ISI cut Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective for the company. in a research note on Friday, December 20th. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Spero Therapeutics in a research report on Thursday, January 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a report on Friday, November 15th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.